drugset / Trial / NCT05203367
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BAR 502 in Healthy Subjects
RandomizedSequentialDouble-blindOther
Summary
This is a prospective, single-center, randomized, double-blind, placebo-controlled, single-ascending dose (SAD) phase 1 study to evaluate the safety and tolerability of single-ascending doses of BAR 502 in healthy male and female subjects.
Timeline
- Start
- 2022-11-25
- Primary completion
- 2023-03-30
- Completion
- 2023-03-30
Outcome
Outcome not reported
Stopped: “Update development program”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BAR502 | Unknown | 10 mg | Oral |
| Subject | BAR502 | Unknown | 50 mg | Oral |
| Subject | BAR502 | Unknown | 150 mg | Oral |
| Subject | BAR502 | Unknown | 300 mg | Oral |